Serum lipid profiles in patients receiving endocrine treatment for breast cancer—the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial

https://doi.org/10.1016/S0753-3322(05)80051-4Get rights and content

Abstract

Background. -

Anti-aromatase therapy is important in the treatment of breast cancer. Cyclooxygenase-2 (COX-2) inhibitors may be effective in chemoprevention. A proof of principle study was performed to investigate the efficacy and side effects including changes in lipid profiles of combining anti-aromatase therapy and COX-2 inhibitor preoperatively in hormone sensitive postmenopausal breast cancers.

Methods. -

From February 2002 to April 2003, 41 postmenopausal women with histologically proven LABC were recruited. The patients were randomly assigned to receive exemestane 25 mg daily and celecoxib 400 mg twice-daily (group A), exemestane 25 mg daily (group B) and letrozole 2.5 mg daily (group C.

Results. -

Observed clinical response rates were 61.5%, 60% and 54.5% for Groups A-C, respectively, with no pathologic complete response. Cholesterol levels for Group A dropped progressively and a statistical difference was observed between fifth week after operation and preoperative level (P= 0.026). In addition, Group A has significantly lowered cholesterol and LDL levels than Groups B and C after 18 weeks of treatment.

Conclusion. -

The initial results show that different neoadjuvant anti-aromatase therapies has similar efficacy but the combination with celecoxib may have an advantageous effects on the serum lipid profiles.

References (18)

  • TsujiiM. et al.

    Cyclooxygenase regulates angiogenesis induced by colon cancer cells

    Cell

    (1998)
  • BrueggemeierR.W. et al.

    Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens

    Cancer Lett

    (1999)
  • LuQ. et al.

    Expression of aromatase protein and messenger ribonucleotide acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers

    Endocrinology

    (1996)
  • GossP.E.

    Anti-aromatase agents in the treatment and prevention of breast cancer

    Cancer Control

    (2002)
  • KokiA.T. et al.

    Celecoxib: a specific COX-2 inhibitor with anticancer properties

    Cancer Control

    (2002)
  • ChowL.W.C. et al.

    Hormonal receptor determination of 1052 Chinese breast cancers

    J Surg Oncol

    (2002)
  • MasferrerJ.L. et al.

    Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors

    Cancer Res

    (2000)
  • HarrisR.E. et al.

    Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor

    Cancer Res

    (2000)
  • HarrisR.E. et al.

    Nonsteroidal anti-inflammatory drugs and breast cancer

    Epidemiology

    (1996)
There are more references available in the full text version of this article.

Cited by (17)

  • Exploration of structural requirements for azole chemicals towards human aromatase CYP19A1 activity: Classification modeling, structure-activity relationships and read-across study

    2022, Toxicology in Vitro
    Citation Excerpt :

    CYP19A1 is mostly present in the peripheral tissues such as fat and muscle, and especially in the breast and ovarian cells of females (Honda et al., 1994; Mahendroo et al., 1991; Simpson et al., 1993; Stocco, 2012; Leshin et al., 1981; Mahendroo et al., 1993). Any disturbance in the aromatase activity induces imbalance of estrogen levels in tissues which further disrupts estrogen mediated physiological responses, leading to endocrine disruption (Blakemore and Naftolin, 2016; Chow et al., 2005; Njar and Brodie, 2015; Aromatase Assay (Human Recombinant) Standard Evaluation Procedure (SEP), 2011; Adhikari et al., 2017a, 2017b; Jha et al., 2015). Many chemical species including pesticides, antifungal and antibacterial substances can influence the CYP19A1 activity in three different ways; i) compounds that can disturb normal functioning of the enzyme by procatalysis are categorized as agonists; ii) some chemical species inhibit the activity of aromatase enzyme for the natural substrate (androgen) and are known as antagonists (or aromatase inhibitors); (iii) Some may also act as allosteric inhibitors (Zhang et al., 2020; Ghosh et al., 2016a, 2016b).

  • Design, synthesis and structure-activity relationship study of novel pyrazole-based heterocycles as potential antitumor agents

    2010, European Journal of Medicinal Chemistry
    Citation Excerpt :

    On the other hand, several authors have reported the inhibitory effects of celecoxib on breast cancer [2–6], recurrent malignant glioma [7], advanced non-small cell lung cancer [8–10], refractory multiple myeloma [11], advanced colorectal cancer [12] and advanced pancreatic cancer [13]. It was proved that celecoxib exerts its antitumor action via inhibition of aromatase, an enzyme complex consisting of a cytochrome P-450 hemoprotein and a flavoprotein, which converts C-19 androgens, such as testosterone and androstenedione, to C-18 estrogen such as estradiol and estrone [14–17]. Therefore, it is useful in controlling the progression of tumors with estrogen receptors; i.e. breast and ovarian tumors.

  • Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer

    2008, Journal of Steroid Biochemistry and Molecular Biology
View all citing articles on Scopus
View full text